Compare SOS & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOS | TPST |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2M | 15.6M |
| IPO Year | 2005 | 2012 |
| Metric | SOS | TPST |
|---|---|---|
| Price | $0.91 | $0.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 17.7K | ★ 126.1K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.90 | $0.84 |
| 52 Week High | $2.89 | $12.22 |
| Indicator | SOS | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 37.96 | 30.47 |
| Support Level | $0.91 | N/A |
| Resistance Level | $1.09 | $1.09 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 10.53 | 11.97 |
SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing and other Hosting services. The company has single reporting segment: Commodity trading and generates key revenue is generated from Commodity trading.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.